Obe-cel Trial in SLE on Track to Be Initiated in Early 2024; Obe-cel’s Development in Oncology Could Accelerate its Path to Market in SLE; Autolus to Leverage Infrastructure Established for ALL in Autoimmune Diseases

On Tuesday, October 24, Autolus held a virtual event (press release / presentation) highlighting its intention to initiate a Ph1 trial evaluating obe-cel (CD19 CAR-T) in systemic lupus erythematosus (SLE) in early 2024, while disclosing the company’s strategy in the autoimmune disease space. Below, Celltelligence provides insights on Autolus’s plans for autoimmune diseases and discusses how obe-cel’s previous development in oncology could be a potential advantage versus its competitors in the space.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.